Clinical research - Today Stories

25-year industry veteran and Biotech business leader recognized among the most inspiring people in life sciences BOSTON and DURHAM, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced Executive Vice President and Global Head of Biotech Jim Anthony has been named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry. Mr. Anthony was recognized for his outstanding leadership, ready-for-anything attitude and relationship-building prowess to grow Parexel’s Biotech business with a Patients-First approach. His leadership has been transformational to the company’s growth while contributing to innovative new…

Marking its 20th global recipient, the grant program supports next-generation sequencing-based research to explore new and expanded applications for molecular testing CARLSBAD, Calif., August 01, 2022 - As part of its continued commitment to expand the benefits of next-generation sequencing (NGS), Thermo Fisher Scientific is now accepting submissions for the fifth round of the Oncomine Clinical Research Grant program. The program supports clinical and translational research that advances the use of genomic testing to unlock the promise of precision medicine for more cancer patients. The program awards independent clinical research teams with financial support worth up to $200,000 in reagents and general funding. Since its introduction in 2020, the Oncomine Clinical Research Grant program…

CRO gains access to genetic testing data, aims to improve global research with enhanced data insights and faster patient recruitment for rare disease studies Research Triangle Park, N.C. – July 12, 2022 –Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), today announced its strategic partnership with Invitae, a leading medical genetics company. The partnership makes Worldwide the first CRO to use Invitae’s Explorer tool – part of its real-world data platform that enables access to aggregated genetic testing results. Around the world, 300 million people have a rare disease, and 72 percent of those diseases have genetic origins (source). This partnership underscores Worldwide’s global leadership in rare dise…

Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.[i]  These findings further offer insight into the treatment of migraine in real-world clinical practice…

Scientific Laboratory Supplies (SLS) – the leading supplier of equipment, chemicals and consumables for laboratory use in the UK – has announced the acquisition of two businesses, Gem Scientific and Northern Balance, to expand its product and service offerings. Both companies will continue to operate as independent entities and retain all employees, whilst harnessing SLS’s business support and infrastructure to benefit all parties, stakeholders and customers.   Gem Scientific is a laboratory equipment distributor based in West Yorkshire, supplying high quality products – including hygiene testing devices and consumables – to sectors such as the food and beverage industry. This acquisition will help to strengthen both brands in this field, giving customers greater access to a wider range of…

Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S. to increase diversity in clinical trials BOSTON, and Durham, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunity for increased diversity in clinical trials. CVS Health®, the leading health care solutions company, and Javara, the leading Integrated Research Organization, have joined the network as inaugural members, opening the door to community-based research site…

Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services. The company’s new facilities in Colwick, Nottingham represent a three-fold increase in the company’s footprint, allowing room for further expansion. The purpose-built facility is an independent building covering approximately 5,500 sq ft of space across two levels. The ground floor is dedicated to laboratory facilities, whilst the first floor provides scientific write-up space, offices, and meeting rooms. The new laboratories are equipped with state-of-the-art imaging and analysis equipment and Class ll biological safety cabinets, fridges, freezers, and CO2 in…

WILMINGTON, N.C., June 08, 2022 - The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London. In addition to the business winning the highest honor again this year, 50 clinical researchers from the company were named finalists within all nine eligible team and individual competition categories. "For the third year in a row, our colleagues have made their presence known by winning multiple recognitions, including the top title, in this highly regarded competition," said Amber Lee, senior vice president, clinical operations, clinical research, Thermo Fisher Scientific. "The unwavering dedication, expertise and passion our colleague…

Innovative Trials, a UK-based clinical trials patient recruitment company, has today (Monday 6 June) announced its intention to help fund research into multiple sclerosis (MS) and contribute towards the MS Society's vision of a world free from the effects of MS. The company, which works with some of the world’s biggest pharmaceutical companies to accelerate the development of life-changing treatments, has chosen the MS Society as its official 2022-23 charity partner and is aiming to raise at least £3,000 for the charity over the next 12 months.  MS is a neurological condition that affects nerves in the body. More than 130,000 people in the UK are living with the condition and around 7,000 people are diagnosed every year [1]. MS is unpredictable and different for everyone, but common sympto…

Today is Clinical Trials Day 2022 – a day dedicated to recognising the people who conduct clinical trials and thanking them for their commitment to improving public health. Lead by the Association of Clinical Research Professionals (ACRP) and powered by Sanofi, Clinical Trials Day raises awareness of clinical trials and of clinical research as a career option. It is celebrated globally on the day that James Lind began what is widely regarded as the first randomised clinical trial aboard a ship on May 20th, 1947. Visit the ACRP website for sharable resources and more information on how you can get involved. Are you looking for a job in Clinical Research? Take a look at the latest vacancies in Clinical Research on PharmiWeb.Jobs here.

WILMINGTON, N.C., May 12, 2022 - The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been distinguished for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG), a leading global technology research and advisory firm. The business was recognized as an ISG Provider Lens Leader for its digital transformation services, including customer solutions for clinical development and patient engagement. This marks the second consecutive year the business has been acknowledged by ISG. In its 2021 ISG Provider Lens Life Sciences Digital Services Global Report, ISG recognized Thermo Fisher's clinical research business with a clinical development leader designation for its skill and dexterity in…

The transaction capitalizes on the two company’s combined geographic strengths, complementary service offerings and therapeutic expertise to advance industry-leading research for improved patient outcomes. WILMINGTON, N.C., ALDERLEY PARK, U.K, 4 May 2022 – Today, Catalyst Clinical Research, a market-leading provider of clinical research services, announced a strategic acquisition of Aptus Clinical to expand the geographic reach of the two companies, and to enhance patient access to advanced, life-changing therapies. Together, the two entities will become one multi-region clinical research organization with an accelerated growth trajectory in both the U.S. and Europe. Catalyst’s offerings will now encompass extensive and expanded clinical consulting services, as it inherits Aptus’ strong an…

WILMINGTON, N.C., April 21, 2022 - The PPD clinical research business of Thermo Fisher Scientific was named "Best Contract Research Organization" at the 15th annual Vaccine Industry Excellence (ViE) Awards during the 2022 World Vaccine Congress, recognizing its success in helping customers develop safe and effective vaccines to improve health and save lives. The honor marks the business' second consecutive year earning "Best CRO" at the ViE Awards and follows recognition at the Citeline Awards as "Clinical Research Team of the Year" with Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally. With more than 30 years of commercial and government vaccine experience, the business has conducted vaccine studies in more than 90 countries and works…

Mobile research – sites an innovative decentralized trial solution – ease barriers to patient participation, improve trial enrollment WILMINGTON, N.C., April 19, 2022 - The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, and Matrix Clinical Trials, a Matrix Medical Network offering, are collaborating to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution. The business is deploying state-of-the-art Matrix mobile research sites and expert clinical staff across the U.S. to help identify, recruit and retain trial participants, while ensuring a positive patient experience. At the same time, the two companies are exploring opportunities to expand the collaboration to additional geographies. Therm…

The Citeline Award recognizes the COVE study, Moderna's Phase III vaccine trial that enrolled more than 30,000 participants across the U.S. WILMINGTON, N.C., April 14, 2022 - The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally, were named "Clinical Research Team of the Year" during the 2021 Citeline Awards. As Moderna's clinical research organization partner, the PPD team, now part of Thermo Fisher, supported Moderna's mRNA-1273-P301 vaccine trials, including its pivotal Phase III COVE study. The study enrolled more than 30,000 participants, ages 18 and older, across 99 U.S. sites in 12 weeks in the summer/fall of 2020. The Citeline Award for "Clinical Research Team of t…

Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism Kynos programmes are focused on three key areas: in critical illness post-surgery; in conditions driven by inflammation; and in cancers where inflammation is preventing the immune system from fighting back £9m financing made up of £6.5m equity financing led by Epidarex Capital, together with IP Group and Scottish Enterprise, alongside £2.5m Innovate UK grant funding for a Phase 1 clinical trial of lead KMO inhibitor Innovative pipeline of first-in-class KMO inhibitors exclusively licensed from the University of Edinburgh after a co-development programme with GSK Company led by industry-experie…

Agreement brings complementary capabilities in clinical, regulatory and scientific affairs for clients in key markets Frankfurt, Germany – 8 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger agreement with Ascent Development Services, a Japan-based leader in enabling the integration of  Asia into global pharmaceutical product development. Founded in 2017, Ascent’s team of experts work with emerging biopharma companies to understand and overcome differences in medical practice, culture and language in order to achieve the optimal strategic and operational integration of Asia into global drug development.  Headquartered in Tokyo, Ascent employs staff across Asia, including China, Korea, M…

EQT Private Equity and Goldman Sachs Asset Management committed to supporting Parexel’s Patients-First focus, track record of clinical excellence and dedication to quality Newly-appointed Board of Directors brings vast experience across life sciences, digital transformation and innovation to guide next phase of transformational journey EQT Private Equity and Goldman Sachs Asset Management to back existing management team led by CEO Jamie Macdonald BOSTON and Durham, N.C. Nov. 15, 2021 — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the completion of its acquisition by EQT IX fund (“EQT Private Equity”) and funds managed by the Private Equity business within Goldman…

Ki-CONNECT collaboration seeks to offer clinical trial benefits to patients and the pharmaceutical industry BOSTON and Durham, N.C. Oct. 20, 2021 — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, and Kyoto University Hospital today announced a strategic alliance aimed at providing more opportunities for clinical research and producing efficient and productive ways of supporting clinical studies. As part of Parexel’s Alliance Site network — consisting of more than 500 sites and over 17,000 investigators across the globe accelerating access to and enrollment of patient populations for clinical trials — Kyoto University Hospital will share their therapeutic expertise and opportunities to…

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany. Telix today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (Merck), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck announced in August 2019. TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. Under t…